






MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis

Jiaofeng Huang ^{1,*}Wenjuan Xue ^{2,*}Mingfang Wang ¹Yinlian Wu ¹Medha Singh ³Yueyong Zhu ^{1,4}Rahul Kumar ⁵Su Lin ¹

¹Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, 350005, People's Republic of China;

²Department of Traditional Chinese Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, 350005, People's Republic of China;

³Department of General Medicine, Tan Tock Seng Hospital, Singapore; ⁴Fujian Key Laboratory of Precision Medicine for Cancer, the First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian, People's Republic of China; ⁵Department of Gastroenterology and Hepatology, Duke-NUS Academic Medical Centre, Changi General Hospital, Singapore

*These authors contributed equally to this work

Introduction: Metabolic associated fatty liver disease (MAFLD) is a novel concept for fatty liver disease. Different from non-alcoholic fatty liver disease (NAFLD), the diagnosis of MAFLD requires the presence of metabolic risks. This study aimed to characterize patients with liver steatosis but without metabolic risks (non-MR-steatosis) which may not be diagnosed by MAFLD criteria.

Methods: Consecutive patients who underwent biopsy were included in this study. The clinic-pathological characteristics of non-MR-steatosis, NAFLD and MAFLD were compared.

Results: A total of 1217 cases were included. There were 426 (35.00%) cases with MAFLD, 585 (48.07%) with NAFLD and 168 (13.80%) with non-MR-steatosis. The majority of the cases were infected with HBV (93.26%). The age and metabolic profiles were highest in MAFLD and lowest in non-MR-steatosis. The body mass index (BMI) level was also lowest in non-MR-steatosis ($20.78 \pm 1.54 \text{ kg/m}^2$). The ALT and AST levels of the non-MR-steatosis group were not statistically different from those of MAFLD or NAFLD groups ($p > 0.05$). Histologically, there was no significant difference in the degrees of inflammation and fibrosis among the three groups. The severity of steatosis in non-MR-steatosis group was lower than MAFLD or NAFLD groups ($p < 0.05$). These results were consistent in both HBV and non-HBV subgroups.

Conclusion: MAFLD criteria may overlook some steatotic patients without metabolic risks, who may also have steatohepatitis and significant fibrosis.

Keywords: metabolic associated fatty liver disease, nonalcoholic fatty liver disease, metabolic risks, lean NAFLD, biopsy

Introduction

Metabolic associated fatty liver disease (MAFLD) is a novel concept proposed by an international consensus in 2020.¹ Significantly different from non-alcoholic fatty liver disease (NAFLD), the diagnosis of MAFLD does not require the exclusion of other chronic liver diseases, while the presence of metabolic abnormality is necessary.²⁻⁵ Studies show the new definition of MAFLD helps to select patients at high intra- and extra-hepatic risk.⁵⁻⁸

The mortality in fatty liver disease is correlated with the severity of liver fibrosis.^{9,10} Our previous data also showed that MAFLD was more practical for identifying fatty liver disease with advanced fibrosis.¹¹ On the other hand, we also found a group of patients with significant hepatic steatosis but without metabolic risks cannot be classified as MAFLD, may thus be undiagnosed. This group of patients could be labeled as non-metabolic related steatosis (non-MR-steatosis).¹²

Correspondence: Su Lin
Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, No. 20, Chazhong Road, Taijiang District, Fuzhou, Fujian, 350005, People's Republic of China
Tel +86 591-87981657
Fax +86 591-87982526
Email sumer5129@fjmu.edu.cn

However, the above two studies on the relationship between liver fibrosis and MAFLD^{11,12} were assessed by non-invasive fibrosis scores, which is suboptimal and inaccurate in MAFLD.¹³ There is a paucity of literature and a knowledge gap in this area as the severity of liver fibrosis is not assessed by the gold standard of liver biopsy. This study aimed to further evaluate the MAFLD criteria in a biopsy-proven cohort and to characterize patients who were currently undiagnosed by MAFLD criteria.

Materials and Methods

Study Population

This is a retrospective study designed to compare the differences between the MAFLD and NAFLD criteria in a liver biopsy cohort. Consecutive patients who underwent liver biopsy at the First Affiliated Hospital of Fujian Medical University between May 2005 and June 2015 were included. The study protocol was approved by the ethics committee of the First Affiliated Hospital of Fujian Medical University.

The inclusion criteria were all patients with biopsy during the study period. The exclusion criteria were as follows: 1) with any cause of acute hepatitis, for instance, acute viral hepatitis or drug-induced hepatitis; 2) autoimmune liver disease; 3) malignancy; 4) with incomplete data of relevant parameters.

This study cohort did not include any patient with excessive alcohol consumption as pathology is not necessary for the diagnosis and management of the alcoholic liver disease.

Diagnostic Criteria and Definition of Groups

MAFLD

MAFLD is diagnosed based on biopsy-proven hepatic steatosis in the presence of any one of the following three metabolic conditions: diabetes mellitus, overweight/obesity, or metabolic dysregulation.⁵ Overweight/obesity is defined as the body mass index (BMI) $\geq 23 \text{ kg/m}^2$. The type 2 diabetes mellitus was diagnosed based on a history of diabetes, and/or fasting plasma glucose $\geq 7.0 \text{ mmol/L}$, or 2-hour glucose $\geq 11.1 \text{ mmol/L}$, and/or glycosylated hemoglobin $\geq 6.5\%$. According to the diagnosis criteria of MAFLD,⁵ metabolic dysregulation was defined when at least two metabolic abnormalities were presented, including the abnormal waist circumference, high blood

pressure, low high-density lipoprotein cholesterol (HDL-C), high blood glucose or homeostasis model assessment-insulin resistance (HOMA-IR) score and high C-reactive protein (CRP).

NAFLD

NAFLD was defined by the presence and pattern of fat accumulation (steatosis) on liver biopsy and by the exclusion of alcohol consumption of $\geq 30 \text{ g/d}$ for males and $\geq 20 \text{ g/d}$ for females or other known causes of liver disease.³ As the concomitance of HBV and NAFLD is popular in China¹⁴ and hepatitis B virus (HBV) infection rate was high in this cohort, we did not exclude those with HBV infection when diagnosing NAFLD, but performed a subgroup study in patients with and without HBV infection to exclude the impact of HBV infection in this study.

Non-MR-Steatosis

Patients with liver steatosis on liver biopsy but without obesity, metabolic dysregulation or type 2 diabetes were defined as non-MR-steatosis.

HBV Infection

The seropositive in hepatitis B surface antigen (HBsAg) for more than 6 months.¹⁵

Demographic Variables

The following demographic variables were obtained from the original database: age, sex, BMI, and the history of hypertension and type 2 diabetes mellitus. BMI was calculated as weight (in kilograms) divided by the square of height (in meters).

Laboratory Parameters

Laboratory measurement studied included fasting plasma glucose (FPG), total bilirubin (TBIL), aspartate aminotransferase (AST), alanine transaminase (ALT), γ -glutamyl transferase (GGT), albumin, blood urea nitrogen (BUN), uric acid, total cholesterol (TC), total triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), HDL-C, very low-density lipoprotein cholesterol (VLDL-C), Hepatitis B e antigen (HBeAg) and HBV DNA. All biochemical assessments were performed by standard laboratory methods.

Histologic Evaluation

All patients enrolled in this study underwent ultrasonography guided percutaneous liver biopsy using a 16-gauge hepatic needle. The liver specimens were immediately immersed in formalin, embedded with paraffin, and stained with

hematoxylin and eosin, and Masson's trichrome. A biopsy tissue with a minimum length of 15 mm and at least 6 portal areas was regarded as sufficient tissue. The liver biopsy specimen was reviewed by two experienced pathologists independently. Fatty liver was defined as the presence of steatosis in at least 5% of hepatocytes. Mild steatosis (S1) was defined if 5–33%, moderate steatosis (S2) if >33–66%, and severe steatosis (S3) if >66% of examined liver surface area was involved with steatosis.¹⁶ The degree of liver inflammation was graded from 0 to 4 points use the Scheuer System.^{17,18} Liver fibrosis was scored from 0 to 4.^{17,18} Advanced fibrosis was defined as fibrosis score ≥ 3 (fibrosis with architectural distortion). Significant inflammation was classified as inflammation grade ≥ 3 .¹⁹ Moderate to severe steatosis was defined as steatosis grade ≥ 2 . NAFLD activity score (NAS) calculates the unweighted sum of the scores for steatosis (0–3), lobular inflammation (0–3) and hepatocellular ballooning (0–2).¹⁶

Statistical Analysis

Continuous variables are expressed as means \pm standard variation (SD) or median (range interquartile). Categorical variables are expressed as percentages. The Mann–Whitney *U*-test (for 2 samples) or the Kruskal–Wallis for One-way Analysis of Variance (for K samples) and Chi-squared test (for categorical variables) were used to investigate the differences between the groups. A multivariate

logistic regression analysis was performed to explore the risk factors for advanced liver fibrosis. All tests were two-tailed and resulted in a *p*-value less than 0.05 were considered statistically significant. All analysis was conducted using R 3.6.2 (<https://www.r-project.org/>) or SPSS 19.0.

Results

Baseline Characteristics of Patients

The consort diagram of population selection for the study is shown in Figure 1. A total of 1217 patients with liver biopsy and complete laboratory data were included. There were 966 (79.38%) males, with a mean age of 37.58 ± 11.28 years, and a mean BMI of 22.97 ± 3.23 kg/m². There were 107 (8.79%) cases with type 2 diabetes and 61 (5.01%) with hypertension. The majority of the cases (1135/1217, 93.26%) were HBsAg seropositive. All of the HBV-infected patients had never received anti-virus treatment before biopsy. Amongst the entire cohort, MAFLD was diagnosed in 426/1217 (35.00%) participants, and NAFLD was diagnosed in 585/1217 (48.07%). Significant inflammation (grade ≥ 3) was found in 609 (50.04%) patients, advanced fibrosis (scores ≥ 3) in 534 (43.88%) patients, and moderate to severe steatosis (grade ≥ 2) in 269 (22.10%) patients.

A total of 168/1217 (13.80%) patients had biopsy proven to have hepatic steatosis but without any metabolic




Figure 1 The flow chart.

risks. These patients were grouped as non-MR-steatosis. Among these 168 patients, 150 (12.24%) were missed diagnosed by both MAFLD. 74/1217 (6.08%) patients were with NAFLD and without HBV infection.

Comparison of MAFLD, NAFLD and Non-MR-Steatosis Groups

The comparison among MAFLD, NAFLD and non-MR-steatosis is illustrated in [Table 1](#). BMI of NAFLD group ($24.17 \pm 3.18 \text{ kg/m}^2$) was significantly lower than that of MAFLD group ($25.51 \pm 2.66 \text{ kg/m}^2$). The other metabolic profiles, including type 2 diabetes, TG, VLDL-C and FPG, were found to be higher in MAFLD population than NAFLD population. However, the difference between liver enzymes, HBeAg and HBV DNA was not statistically significant between NAFLD and MAFLD groups ($P > 0.05$). The proportion of moderate to severe steatosis was 50.70% in the MAFLD group and 44.44% in the NAFLD group, but the difference did not reach statistical significance ($P = 0.057$). Similarly, there was no significant difference in inflammation and fibrosis between these two groups.

Patients in the non-MR-steatosis group had very different anthropometric and clinical characteristics compared to MAFLD and NAFLD groups: they were the youngest (37.05 ± 11.21 years) among the three groups and had the lowest mean BMI level ($20.78 \pm 1.54 \text{ kg/m}^2$). None of these patients had type 2 diabetes and only 4 (2.38%) patients had hypertension. The serum lipids and the serum glucose-related indexes were all within normal range and were significantly lower than those of the MAFLD or NAFLD groups. The median serum ALT and AST levels of the non-MR-steatosis group were not different from the NAFLD and MAFLD groups ($P > 0.05$). Histologically, there was no significant difference among the three groups in inflammation and advanced fibrosis, while the grade of steatosis in non-MR-steatosis group was lower than the MAFLD or NAFLD groups.

The Comparison of MAFLD, NAFLD, and Overlap Group

A total of 417 patients met the criteria of both MAFLD and NAFLD (overlap group). The comparison between MAFLD, NAFLD and the overlap group are shown in [Supplementary Table 1](#). Overall, the features of overlap group were more similar to those of MAFLD. The overlap group had significantly higher BMI, blood lipids, and blood glucose than NAFLD. As for liver histopathology,

no significant difference was found among the three groups. The multivariate logistic regression showed that males, higher ALT level and significant inflammation were independent risk factors for liver fibrosis ($P < 0.05$, detailed in [Supplementary Table 2](#)). However, the severity of hepatic steatosis was not independently associated with advanced fibrosis ($P > 0.05$).

Comparison Among MAFLD, NAFLD and Non-MR-Steatosis Groups in the Non-HBV Population

[Table 2](#) shows the characteristics of 82 cases without HBV infection. Among these patients, 60/82 (73.17%) were diagnosed as MAFLD, 74/82 (90.24%) as NAFLD, and 18/82 (21.95%) as non-MR-steatosis. These three groups were significantly different in BMI ($25.3 \pm 3.35 \text{ kg/m}^2$, $24.20 \pm 3.38 \text{ kg/m}^2$ and $20.97 \pm 1.25 \text{ kg/m}^2$, respectively, $P < 0.001$). Non-MR-steatosis group had significantly lower VLDL-C and FPG levels than NAFLD and MAFLD groups, however, other indicators including liver function and kidney function did not differ significantly among the three groups ($P > 0.05$). The proportion of significant inflammation, advanced fibrosis, and moderate to severe steatosis in non-MR-steatosis group was 11.11%, 11.11% and 66.67%, respectively, which was not different from the NAFLD and MAFLD group. As for NAS scores, there was no significant difference between the three groups.

Comparison Among MAFLD, NAFLD and Non-MR-Steatosis Groups in the HBV-Infected Population

[Table 3](#) shows the characteristics of 1135 patients with HBV infection. Patients in the non-MR-steatosis group showed less metabolic profiles such as BMI, type 2 diabetes, blood lipids and blood glucose. The HBeAg positivity and HBV DNA level of the non-MR-steatosis group was not much different from those of MAFLD or NAFLD groups. The proportion of severe steatosis in the non-MR-steatosis group was lower than the other two groups while the inflammation and fibrosis were not significantly different among the three groups.

Discussion

The concept “MAFLD” is expected to change the management of fatty liver disease.⁴ This study compares the clinicopathological characteristics of MAFLD and

Table I Comparison Between MAFLD, NAFLD and Non-MR-Steatosis

Variables	MAFLD	NAFLD	Non-MR-Steatosis	P		
				MAFLD vs NAFLD	MAFLD vs Non-MR-Steatosis	NAFLD vs Non-MR-Steatosis
N	426	585	168			
Age (years)	40.39 ± 10.97	39.41 ± 11.10	37.05 ± 11.21	0.155	0.001	0.011
Male, n (%)	361 (84.74)	489 (83.59)	133 (79.17)	0.684	0.130	0.223
BMI (kg/m ²)	25.51 ± 2.66	24.17 ± 3.18	20.78 ± 1.54	< 0.001	< 0.001	< 0.001
Waist circumference (cm)	84.10 ± 7.32	84.69 ± 6.82	86.10 ± 5.53	0.740	0.445	0.572
Type 2 diabetes, n (%)	83 (19.48)	81 (13.85)	0 (0)	0.021	< 0.001	< 0.001
Hypertension, n (%)	42 (9.86)	45 (7.69)	4 (2.38)	0.272	0.004	0.022
HBsAg positive, n (%)	366 (85.92)	511 (87.35)	150 (89.29)	0.568	0.337	0.588
Log HBVDNA (IU/mL)	4.88 ± 2.24	4.97 ± 2.20	5.11 ± 2.13	0.536	0.292	0.515
HBeAg positive, n (%)	208 (48.83)	302 (51.62)	97 (57.74)	0.425	0.067	0.182
TBIL (μmol/L)	18.44 ± 21.50	18.15 ± 21.4	17.4 ± 21.02	0.916	0.683	0.725
Albumin (g/L)	42.58 ± 4.95	42.52 ± 5.05	42.25 ± 5.24	0.759	0.299	0.389
ALT (U/L)	65 (41, 144)	67 (41, 141.75)	75.5 (40, 138.75)	0.901	0.713	0.771
AST (U/L)	42 (30, 71)	43 (30, 77.75)	45 (32, 82.25)	0.730	0.291	0.400
GGT (U/L)	53 (31, 100)	49 (29, 91)	43 (27, 74)	0.133	0.001	0.024
Creatinine (μmol/L)	73.35 ± 13.82	73.77 ± 17.99	74.19 ± 26.07	0.927	0.789	0.729
eGFR (mL/min)	120.87 ± 32.47	121.83 ± 37.01	125.86 ± 47.02	0.875	0.364	0.404
Uric acid (μmol/L)	369.22 ± 82.29	362.59 ± 83.01	345.03 ± 81.38	0.239	0.004	0.031
TC (mmol/L)	4.77 ± 1.13	4.74 ± 1.08	4.63 ± 0.87	0.749	0.312	0.411
TG (mmol/L)	1.68 ± 1.24	1.50 ± 1.11	1.07 ± 0.43	< 0.001	< 0.001	< 0.001
LDL-C (mmol/L)	2.90 ± 0.97	2.84 ± 0.94	2.69 ± 0.82	0.457	0.014	0.117
HDL-C (mmol/L)	1.12 ± 0.30	1.19 ± 0.34	1.36 ± 0.38	0.002	0.043	< 0.001
VLDL-C (mmol/L)	0.51 ± 0.38	0.46 ± 0.35	0.29 ± 0.15	0.003	< 0.001	< 0.001
FPG (mmol/L)	5.34 ± 1.42	5.14 ± 1.23	4.71 ± 0.54	0.005	< 0.001	< 0.001
HOMA-IR	3.58 ± 1.81	3.20 ± 1.81	1.97 ± 1.21	0.244	0.001	0.007
CRP (mg/L)	3.61 ± 5.56	3.66 ± 5.21	3.89 ± 4.53	0.928	0.997	0.985
Platelets (×10 ⁹ /L)	204.71 ± 64.30	200.89 ± 63.37	193.1 ± 66.78	0.376	0.042	0.139
Histopathological Features						
Significant inflammation (G≥3, n (%))	168 (39.44)	234 (40.00)	71 (42.26)	0.908	0.590	0.662
Advanced fibrosis (F≥3, n (%))	157 (36.85)	214 (36.58)	60 (35.71)	0.982	0.869	0.909
Moderate to severe steatosis (S≥2, n (%))	216 (50.70)	260 (44.44)	52 (30.95)	0.057	< 0.001	0.002

Notes: Categorical values are shown as n (%). Continuous variables are shown as mean ± standard deviation or median [interquartile range].

Abbreviations: MAFLD, metabolic associated fatty liver disease; NAFLD, nonalcoholic fatty liver disease; Non-MR-steatosis, non-metabolic risks NAFLD; BMI, body mass index; HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transpeptidase; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; VLDL-C, very low density lipoprotein cholesterol; FPG, fasting plasma glucose; HOMA-IR, Homeostasis model assessment-insulin resistance score; CRP, C-reactive protein.

NAFLD in a large biopsy-proven cohort. The main finding of our study is that there is no difference in steatosis and liver inflammation/fibrosis between MAFLD and NAFLD. Another important finding of our study is that a small group of patients with advanced fibrosis might be missed out by MAFLD criteria. These undiagnosed cases are lean and have fewer metabolic risks, but they still have severe inflammation and fibrosis in liver pathology. This specific subgroup of patients namely non-MR-steatosis exists regardless of the concomitant HBV infection.

The results of our study showed that non-MR-steatosis patients seemed to be much healthier from the angle of metabolic syndromes, for example, they were much younger than NAFLD and MAFLD, with the lowest BMI and normal metabolic profiles. This is not a surprising finding. However, their liver enzymes, including ALT, AST and GGT, were as high as those of MAFLD and NAFLD populations. The significant liver injury in non-MR-steatosis group was further evident by histopathological characteristics which showed that the extent of the inflammation and

Table 2 Comparison Between MAFLD, NAFLD and Non-MR-Steatosis Groups in Non-HBV Population

Variables	MAFLD	NAFLD	Non-MR-Steatosis	P		
				MAFLD vs NAFLD	MAFLD vs Non-MR-Steatosis	NAFLD vs Non-MR-Steatosis
N	60	74	18			
Age (years)	41.62 ± 15.26	40.01 ± 14.81	37.00 ± 12.85	0.559	0.288	0.488
Male, n (%)	36 (60)	48 (64.86)	13 (72.22)	0.690	0.507	0.753
BMI (kg/m ²)	25.3 ± 3.35	24.20 ± 3.38	20.97 ± 1.25	0.024	< 0.001	< 0.001
Type 2 diabetes, n (%)	17 (28.33)	16 (21.62)	0 (0)	0.487	0.008	0.035
Hypertension, n (%)	16 (26.67)	16 (21.62)	1 (5.56)	0.633	0.100	0.177
TBIL (μmol/L)	22.91 ± 25.30	20.84 ± 22.97	12.71 ± 3.19	0.830	0.288	0.316
Albumin (g/L)	44.11 ± 6.34	44.35 ± 6.04	44.26 ± 4.34	0.705	0.746	0.909
ALT (U/L)	85 (48, 144.25)	101 (50, 158)	127 (49.5, 207.5)	0.616	0.454	0.633
AST (U/L)	46 (33.25, 66)	48 (32.5, 78.5)	61 (34, 80.5)	0.729	0.638	0.785
GGT (U/L)	103 (59, 230.25)	105 (53.5, 204)	105 (49, 139.5)	0.708	0.208	0.300
Creatinine (μmol/L)	67.32 ± 14.53	67.56 ± 14.95	65.46 ± 17.06	0.891	0.743	0.712
eGFR (mL/min)	136.3 ± 38.63	136.44 ± 39.69	142.19 ± 43.27	0.972	0.694	0.690
Uric acid (μmol/L)	356.67 ± 76.29	354.23 ± 80.54	337.93 ± 100.08	0.711	0.190	0.256
TC (mmol/L)	4.91 ± 1.08	4.97 ± 1.07	4.98 ± 0.96	0.688	0.629	0.811
TG (mmol/L)	2.12 ± 2.26	1.97 ± 2.05	1.40 ± 0.29	0.518	0.091	0.216
LDL-C (mmol/L)	2.91 ± 1.04	2.95 ± 1.01	3.08 ± 0.69	0.790	0.581	0.733
HDL-C (mmol/L)	1.13 ± 0.35	1.18 ± 0.37	1.26 ± 0.42	0.616	0.458	0.675
VLDL-C (mmol/L)	0.65 ± 0.51	0.61 ± 0.49	0.35 ± 0.16	0.418	0.006	0.023
FPG (mmol/L)	5.42 ± 1.03	5.27 ± 0.95	4.88 ± 0.44	0.289	0.013	0.062
Platelets (×10 ⁹ /L)	240.27 ± 77.17	237.01 ± 74.12	224.86 ± 47.21	0.754	0.440	0.540
Histopathological Features						
Significant inflammation (G≥3, n (%))	11 (18.33)	12 (16.22)	2 (11.11)	0.926	0.721	0.729
Advanced fibrosis (F≥3, n (%))	9 (15.00)	10 (13.51)	2 (11.11)	1.000	1.000	1.000
Moderate to severe steatosis (S≥2, n (%))	49 (81.67)	58 (78.38)	12 (66.67)	0.798	0.201	0.357
NAS score	4.38 ± 1.55	4.27 ± 1.59	3.89 ± 1.68	0.712	0.338	0.457

Notes: Categorical values are shown as n (%). Continuous variables are shown as mean ± standard deviation or median [interquartile range].

Abbreviations: MAFLD, metabolic associated fatty liver disease; NAFLD, nonalcoholic fatty liver disease; Non-MR-steatosis, non-metabolic risks NAFLD; BMI, body mass index; HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transpeptidase; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; VLDL-C, very low density lipoprotein cholesterol; FPG, fasting plasma glucose.

the degree of fibrosis was not different from the other two groups. The result remained consistent in HBV and non-HBV subgroups in this cohort, indicating the hepatic steatosis itself may lead to liver injury. Similarly, our previous study based on the National Health and Nutrition Examination Survey dataset also showed that, a group of steatotic patients who had advanced fibrosis assessed by non-invasive scores will be undiagnosed by MAFLD criteria.¹² Taken together, these results strongly suggest the novel MAFLD criteria may miss out on some steatotic patients with extensive liver injury.

The clinical, biochemical and histopathological characteristics of non-MR-steatosis are similar to that of lean NAFLD, which is known to have normal BMI and a very low proportion of type 2 diabetes (0.6%), hypertension

(1.8%), metabolic syndrome (1.4%), dyslipidemia (2.8%), or obesity (2.0%).²⁰ Patients with lean NAFLD still at high risk of having advanced grade steatohepatitis or fibrosis.²¹ The long-term follow-up studies had illustrated considerable all-cause mortality, liver-related mortality,²² and an increased risk of advanced liver disease²³ in the lean NAFLD population. All these studies underline the importance of the identification of patients with lean NAFLD as they may have an equivalent risk of disease progression and liver-related mortality. However, some lean NAFLD may have no metabolic dysfunction thus being missed diagnosed by MAFLD. In the light of MAFLD, there is no place for this specific group and this will eventually lead to missed opportunities for meaningful interventions in this group of patients.

Table 3 Comparison Between MAFLD, NAFLD and Non-MR-Steatosis Groups in HBV-Infected Population

Variables	MAFLD	NAFLD	Non-MR-Steatosis	P		
				MAFLD vs NAFLD	MAFLD vs Non-MR-Steatosis	NAFLD vs Non-MR-Steatosis
N	366	511	150			
Age (years)	40.19 ± 10.10	39.32 ± 10.47	37.06 ± 11.05	0.208	0.001	0.014
Male, n (%)	325 (88.80)	441 (86.3)	120 (80)	0.320	0.013	0.078
BMI (kg/m ²)	25.54 ± 2.53	24.17 ± 3.16	20.76 ± 1.58	< 0.001	< 0.001	< 0.001
Waist circumference (cm)	84.28 ± 7.43	84.83 ± 6.87	86.10 ± 5.53	0.777	0.524	0.640
Type 2 diabetes, n (%)	66 (18.03)	65 (12.72)	0 (0)	0.037	< 0.001	< 0.001
Hypertension, n (%)	26 (7.10)	29 (5.68)	3 (2.00)	0.472	0.038	0.104
Log HBVDNA (IU/mL)	5.06 ± 2.14	5.13 ± 2.11	5.29 ± 2.01	0.613	0.291	0.463
HBeAg positive, n (%)	163 (44.54)	235 (45.99)	73 (48.67)	0.670	0.392	0.563
TBIL (μmol/L)	17.71 ± 20.75	17.78 ± 21.17	17.85 ± 21.94	0.993	0.984	0.989
Albumin (g/L)	42.33 ± 4.64	42.26 ± 4.85	42.05 ± 5.29	0.724	0.326	0.444
ALT (U/L)	62 (40, 142)	65 (39.5, 139)	73 (39.5, 129)	0.959	0.738	0.755
AST (U/L)	42 (30, 72)	42 (30, 77)	44 (32, 81.5)	0.778	0.314	0.401
GGT (U/L)	48 (30, 81)	46 (29, 75)	40 (27, 68)	0.204	0.007	0.056
Creatinine (μmol/L)	74.41 ± 13.44	74.65 ± 18.22	74.90 ± 26.59	0.863	0.524	0.589
eGFR (mL/min)	118.15 ± 30.53	119.76 ± 36.18	124.51 ± 47.21	0.657	0.179	0.281
Uric acid (μmol/L)	371.38 ± 83.19	363.75 ± 83.36	345.60 ± 80.09	0.233	0.005	0.044
TC (mmol/L)	4.74 ± 1.14	4.71 ± 1.08	4.6 ± 0.86	0.676	0.289	0.424
TG (mmol/L)	1.61 ± 0.96	1.44 ± 0.88	1.03 ± 0.43	< 0.001	< 0.001	< 0.001
LDL-C (mmol/L)	2.89 ± 0.95	2.83 ± 0.93	2.65 ± 0.83	0.376	0.023	0.083
HDL-C (mmol/L)	1.12 ± 0.3	1.20 ± 0.34	1.37 ± 0.38	0.002	< 0.001	< 0.001
VLDL-C (mmol/L)	0.49 ± 0.35	0.44 ± 0.32	0.28 ± 0.15	0.005	< 0.001	< 0.001
FPG (mmol/L)	5.32 ± 1.47	5.12 ± 1.27	4.68 ± 0.55	0.011	< 0.001	< 0.001
HOMA-IR	3.53 ± 1.84	3.15 ± 1.82	1.97 ± 1.21	0.252	0.001	0.011
CRP (mg/L)	2.78 ± 5.03	3.01 ± 4.71	3.40 ± 4.53	0.587	0.711	0.758
Platelets (×10 ⁹ /L)	198.87 ± 60.06	195.76 ± 60.03	189.75 ± 67.79	0.467	0.071	0.180
Histopathological Features						
Significant inflammation (G≥3, n (%))	157 (42.90)	222 (43.44)	69 (46.00)	0.926	0.584	0.645
Advanced fibrosis (F≥3, n (%))	148 (40.44)	204 (39.92)	58 (38.67)	0.933	0.784	0.856
Moderate to severe steatosis (S≥2, n (%))	167 (45.63)	202 (39.53)	40 (26.67)	0.083	< 0.001	0.005

Notes: Categorical values are shown as n (%). Continuous variables are shown as mean ± standard deviation or median [interquartile range].

Abbreviations: MAFLD, metabolic associated fatty liver disease; NAFLD, nonalcoholic fatty liver disease; Non-MR-steatosis, non-metabolic risks NAFLD; BMI, body mass index; HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transpeptidase; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; VLDL-C, very low density lipoprotein cholesterol; FPG, fasting plasma glucose; HOMA-IR, Homeostasis model assessment-insulin resistance score; CRP, C-reactive protein.

It is worth noting that most patients included in our study were having elevated liver enzymes and were clinically suspected to have liver cell injury which was further evaluated with a liver biopsy. Although serum ALT and AST are not sensitive biomarkers for hepatocellular injury in patients with hepatic steatosis,²⁴ the results indicated the role of elevated liver enzymes for diagnostic criteria of MAFLD should also be considered.

The strength of this study is that to our knowledge this is the first study to evaluate the diagnostic criteria of MAFLD based on liver histopathology. Our study should however be

interpreted in light of some limitations. First, the study cohort is from a single center with a high proportion of HBV and low BMI, which is a common occurrence in Asian countries,^{25,26} limiting the generality of our results to the western population. But at least the results of this study apply to a subset of MAFLD namely “HBV-MAFLD”, which is the most important subtype of MAFLD in clinical practice in Asia. Second, compared with our previous population-based study,¹¹ this study only included highly selected patients who underwent liver biopsy, however, it is also fairly common in clinical practice where liver biopsy is only performed in those who

were highly suspected to have a liver injury. Third, there were only 82 cases in the non-HBV subgroup, which might lead to type II errors in statistical analysis. But in line with our previous study in which the NHANES database was used, the fibrosis assessed by non-invasive models was also significant in some non-MR-steatosis cases.¹² Nevertheless, more evidence is needed to verify this conclusion. At last, we did not conclude patients with excessive alcohol consumption because those patients seldom received liver biopsies in our department. In another study, we showed that MAFLD with excessive alcohol consumption has less number of metabolic conditions but equally severe liver injury.²⁷ Moreover, in patients with MAFLD, even mild alcohol consumption is associated with worsening of hepatic fibrosis measures.^{28,29} Thus for patients with alcohol consumption, more aggressive management are needed.

In conclusion, MAFLD criteria may overlook a proportion of patients with non-metabolic related steatohepatitis and significant fibrosis.

Abbreviations

FLD, fatty liver disease; MAFLD, metabolic associated fatty liver disease; NAFLD, nonalcoholic fatty liver disease; Non-MR-steatosis, Non-metabolic risks NAFLD; NAS, NAFLD activity score; BMI, body mass index; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ -glutamyl transpeptidase; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; TC, total cholesterol; VLDL-C, very low-density lipoprotein cholesterol; FPG, fasting plasma glucose; HOMA-IR, homeostasis model assessment-insulin resistance score; CRP, C-reactive protein.

Ethics Approval and Informed Consent

An informed consent was obtained from each participant on admission to use their medical data anonymously. The ethics approval was approved by the First Affiliated Hospital, Fujian Medical University Institution Review Board ([2015]084-1). This study conforms to the principles outlined in the Declaration of Helsinki.

Author Contributions

Jiaofeng Huang and Wenjuan Xue, share first authorship. Study concept and design: Jiaofeng Huang and Su Lin

Acquisition, cleaning of data: Wenjuan Xue and Mingfang Wang

Drafting of the manuscript: Su Lin and Jiaofeng Huang

Critical revision: Rahul Kumar, Yueyong Zhu, Medha Singh and Yinlian Wu

Statistical analysis: Jiaofeng Huang and Wenjuan Xue

Study supervision: Su Lin

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding

This research is supported by Qingzhong Medical Science Research Fund (B17344) and Startup Fund for scientific research, Fujian Medical University (2018QH1047).

Disclosure

The authors declare that they have no competing interests in this work.

References

1. Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. *Gastroenterology*. 2020;158(7):1999–2014.e1991. doi:10.1053/j.gastro.2019.11.312
2. Valenti L, Pelusi S. Redefining fatty liver disease classification in 2020. *Liver Int*. 2020;40(5):1016–1017. doi:10.1111/liv.14430
3. EASL E. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol*. 2016;64(6):1388–1402. doi:10.1016/j.jhep.2015.11.004
4. Fouad Y, Waked I, Bollipo S, et al. What's in a name? Renaming 'NAFLD' to 'MAFLD'. *Liver Int*. 2020;40(6):1254–1261. doi:10.1111/liv.14478
5. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. *J Hepatol*. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
6. Wai-Sun Wong V, Lai-Hung Wong G, Woo J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. *Clin Gastroenterol Hepatol*. 2020. doi:10.1016/j.cgh.2020.10.046
7. Zheng KI, Sun DQ, Jin Y, et al. Clinical utility of the MAFLD definition. *J Hepatol*. 2021;74(4):989–991. doi:10.1016/j.jhep.2020.12.016
8. Sun DQ, Jin Y, Wang TY, et al. MAFLD and risk of CKD. *Metabolism*. 2021;115:154433. doi:10.1016/j.metabol.2020.154433
9. Majumdar A, Tsochatzis E. Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. *Metabolism*. 2020;111:154291. doi:10.1016/j.metabol.2020.154291

10. Cotter T, Dong L, Holmen J, et al. Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system. *J Gastroenterol.* **2020**;55(7):722–730. doi:10.1007/s00535-020-01684-w
11. Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. *Liver Int.* **2020**;40(9):2082–2089. doi:10.1111/liv.14548
12. Huang J, Kumar R, Wang M, et al. MAFLD criteria overlooks a number of patients with severe steatosis: is it clinically relevant? *J Hepatol.* **2020**;73(5):1265–1267. doi:10.1016/j.jhep.2020.06.016
13. Wu Y, Kumar R, Huang J, et al. FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD). *J Hepatol.* **2021**;74(1):247–248. doi:10.1016/j.jhep.2020.06.040
14. Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. *Hepatology.* **2014**;60(6):2099–2108. doi:10.1002/hep.27406
15. Bell S, Lau A, Thompson A, et al. Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients. *J Clin Virol.* **2005**;32(2):122–127. doi:10.1016/j.jcv.2004.10.009
16. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology.* **2005**;41(6):1313–1321. doi:10.1002/hep.20701
17. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. *Hepatology.* **2000**;31(1):241–246. doi:10.1002/hep.510310136
18. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. *J Hepatol.* **1991**;13(3):372–374. doi:10.1016/0168-8278(91)90084-O
19. Hong M, Zhang R, Chen G, et al. Liver stiffness measurement-based scoring system for significant inflammation related to chronic hepatitis B. *PLoS One.* **2014**;9(10):e111641. doi:10.1371/journal.pone.0111641
20. Lu FB, Zheng KI, Rios RS, et al. Global epidemiology of lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. *J Gastroenterol Hepatol.* **2020**;35(12):2041–2050. doi:10.1111/jgh.15156
21. Eslam M, Fan JG, Mendez-Sanchez N. Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health. *Lancet Gastroenterol Hepatol.* **2020**;5(8):713–715. doi:10.1016/S2468-1253(20)30090-X
22. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol.* **2020**;5(8):739–752. doi:10.1016/S2468-1253(20)30077-7
23. Hagström H, Nasr P, Ekstedt M, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study. *Hepatol Commun.* **2018**;2(1):48–57. doi:10.1002/hep4.1124
24. Francque S, Laleman W, Verbeke L, et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. *Lab Invest.* **2012**;92(10):1428–1439. doi:10.1038/labinvest.2012.103
25. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet.* **2004**;363(9403):157–163. doi:10.1016/S0140-6736(03)15268-3
26. Huang J, Jing M, Wang C, et al. The impact of hepatitis B virus infection status on the prevalence of nonalcoholic fatty liver disease: a population-based study. *J Med Virol.* **2020**;92(8):1191–1197. doi:10.1002/jmv.25621
27. Huang J, Ou W, Wang M, et al. MAFLD criteria guide the subtyping of patients with fatty liver disease. *Risk Manag Healthc Policy.* **2021**;14:491–501. doi:10.2147/RMHP.S285880
28. Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. *Liver Int.* **2020**;40(12):3018–3030. doi:10.1111/liv.14675
29. Wang MF, Wan B, Wu YL, et al. Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection. *World J Gastroenterol.* **2021**;27(4):336–344. doi:10.3748/wjg.v27.i4.336

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion

and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal>